Abnormal Expression of WSB1 in Lung Adenocarcinoma: A Potential Prognostic and Immunotherapeutic Sensitivity Biomarker. Advances in World Medical Research, [S. l.], v. 1, n. 2, p. 48–63, 2025. DOI: 10.71204/1bcv8650. Disponível em: https://awmr.cscholar.com/article/view/1000360. Acesso em: 11 feb. 2026.